Orphan/Fast Track Phanes has FDA orphan drug and Fast Track designations for spevatamig and peluntamig, highlighting regulatory incentives and potential expedited paths that can be leveraged in partnering discussions and co-development opportunities.

Phase 2 Momentum Multiple Phase 2 trials for spevatamig, peluntamig, and mavrostobart with ongoing monotherapy and combination therapy in metastatic pancreatic cancer indicate a robust clinical progression and near-term collaboration or licensing opportunities around late-stage readouts.

PDAC Focus Lead asset spevatamig targets claudin 18.2 and CD47 in pancreatic cancer and has global dosing with a growing patient base; potential for partnerships with oncology centers, patient access programs, and regional licensing in high-need PDAC markets.

Strategic Platforms Proprietary platforms PACbody SPECpair and ATACCbody enable rapid generation of bispecific antibodies; these can be shown as a value proposition for potential partners seeking to co-develop next-gen cancer biologics or expand bispecific pipelines.

Clinical/BD pairing Recent high-visibility conference activity and positive Phase 2 updates at ASCO and AACR provide talking points for BD outreach to academic centers, pharma collaborators, and regional partners seeking collaborative trials or equity-based licensing on promising oncology assets.